Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $42.88 USD
Change Today +0.07 / 0.16%
Volume 236.0K
SGEN On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 10:16 AM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

seattle genetics inc (SGEN) Key Developments

Seattle Genetics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Seattle Genetics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues were $82.2 million, compared to $68.3 million in the first quarter of 2014. Net loss was $21.7 million, or $0.17 per share, compared to a net loss of $16.3 million, or $0.13 per share, for the first quarter of 2014. Loss from operations was $21.743 million against $16.371 million a year ago.

Seattle Genetics, Inc. Presents at Credit Suisse 2015 Antibody Day, May-06-2015 02:25 PM

Seattle Genetics, Inc. Presents at Credit Suisse 2015 Antibody Day, May-06-2015 02:25 PM. Venue: Credit Suisse, One Madison Avenue at 24th Street, 12th Floor, New York, New York, United States. Speakers: Jonathan Drachman, Chief Medical Officer and Executive Vice President of Research & Development.

Seattle Genetics, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 10:40 AM

Seattle Genetics, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 10:40 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Clay B. Siegall, Co-Founder, Chairman, Chief Executive Officer and President.

Seattle Genetics, Inc. Presents at UBS Global Healthcare Conference, May-19-2015 02:00 PM

Seattle Genetics, Inc. Presents at UBS Global Healthcare Conference, May-19-2015 02:00 PM. Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Eric L. Dobmeier, Chief Operating Officer.

FDA Accepts Supplemental BLA and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in the AETHERA Setting for the Post-Transplant Consolidation Treatment of Hodgkin Lymphoma Patients at High Risk of Relapse

Seattle Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) for ADCETRIS (brentuximab vedotin) in the AETHERA setting for the post-transplant consolidation treatment of Hodgkin lymphoma (HL) patients at high risk of relapse or progression. The FDA granted Priority Review for the application and the Prescription Drug User Fee Act (PDUFA) target action date is August 18, 2015. The submission of the supplemental BLA is based on positive results from a phase 3 clinical trial called AETHERA that was designed to determine if 16 cycles of ADCETRIS as consolidation therapy immediately following an autologous stem cell transplant (ASCT) could extend progression-free survival (PFS) in HL patients at high risk of relapse or progression. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical HL and systemic anaplastic large cell lymphoma (sALCL), as well as other lymphoma subtypes. ADCETRIS is approved in relapsed HL and sALCL but is currently not approved for consolidation therapy in HL patients immediately after ASCT.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGEN:US $42.88 USD +0.07

SGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $9.03 USD +0.07
Genmab A/S kr576.50 DKK -5.50
Insys Therapeutics Inc $60.49 USD +0.77
MorphoSys AG €67.92 EUR +0.47
Pfizer Ltd/India 2,243 INR +9.70
View Industry Companies
 

Industry Analysis

SGEN

Industry Average

Valuation SGEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.9x
Price/Book 25.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEATTLE GENETICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.